Department of Gastrointestinal Surgery, Peking University People's Hospital, Beijing, 100044, People's Republic of China.
Laboratory of Surgical Oncology, Peking University People's Hospital, Beijing, 100044, People's Republic of China.
World J Surg Oncol. 2022 Sep 24;20(1):308. doi: 10.1186/s12957-022-02766-0.
Pylorus-preserving gastrectomy (PPG) is a function-preserving surgery for the treatment of early gastric cancer (EGC) in the middle third of the stomach. According to the literature reports, PPG decreases the incidence of dumping syndrome, bile reflux, gallstone formation, and nutritional deficit compared with conventional distal gastrectomy (CDG). However, the debates about PPG have been dominated by the incomplete lymphadenectomy and oncological safety. We carried out a systematic review and meta-analysis to evaluate the pathological and oncological outcomes of PPG.
The protocol was registered in PROSPERO under number CRD42022304677. Databases including PubMed, Embase, Web of Science, and the Cochrane Register of Controlled Trials were searched before February 21, 2022. The outcomes included the pooled odds ratios (ORs) for dichotomous variables and weighted mean differences (WMDs) for continuous variables. For all outcomes, 95% confidence intervals (CIs) were calculated. Meta-analysis was performed using STATA software (Stata 14, Stata Corporation, Texas) and Review Manager 5.4.
A total of 4500 patients from 16 studies were included. Compared with the CDG group, the PPG group had fewer lymph nodes harvested (WMD= -3.09; 95% CI -4.75 to -1.43; P < 0.001). Differences in the number of resected lymph nodes were observed at stations No. 5, No. 6, No. 9, and No. 11p. There were no differences in lymph node metastasis at each station. Shorter proximal resection margins (WMD = -0.554; 95% CI -0.999 to -0.108; P = 0.015) and distal resection margins (WMD = -1.569; 95% CI -3.132 to -0.007; P = 0.049) were observed in the PPG group. There were no significant differences in pathological T1a stage (OR = 0.99; 95% CI 0.80 to 1.23; P = 0.88), T1b stage (OR = 1.01; 95% CI 0.81 to 1.26; P = 0.88), N0 stage (OR = 0.97; 95% CI 0.63 to 1.48; P = 0.88), tumor size (WMD = -0.10; 95% CI -0.25 to 0.05; P = 0.187), differentiated carcinoma (OR = 1.04; 95% CI 0.74 to 1.47; P = 0.812) or signet ring cell carcinoma (OR = 1.22; 95% CI 0.90 to 1.64; P = 0.198). No significant differences were observed between the groups in terms of overall survival (HR = 0.63; 95% CI 0.24 to 1.67; P = 0.852) or recurrence-free survival (HR = 0.29; 95% CI 0.03 to 2.67; P = 0.900).
The meta-analysis of existing evidence demonstrated that the survival outcomes of PPG may be comparable to those of CDG. However, fewer lymph nodes at stations in No. 5, No. 6, No. 9, and No. 11p were harvested with PPG. We also found shorter proximal resection margins and distal resection margins for PPG, meaning more remnant stomachs would be preserved in PPG.
保留幽门的胃切除术(PPG)是治疗胃中部早期胃癌(EGC)的一种保留功能的手术。根据文献报道,与传统的远端胃切除术(CDG)相比,PPG 可降低倾倒综合征、胆汁反流、胆结石形成和营养缺乏的发生率。然而,关于 PPG 的争论一直被不完全的淋巴结清扫和肿瘤安全性所主导。我们进行了一项系统评价和荟萃分析,以评估 PPG 的病理和肿瘤学结果。
该方案已在 PROSPERO 中注册,编号为 CRD42022304677。在 2022 年 2 月 21 日之前,检索了包括 PubMed、Embase、Web of Science 和 Cochrane 对照试验登记册在内的数据库。结果包括二分类变量的汇总优势比(OR)和连续变量的加权均数差(WMD)。对于所有结果,计算了 95%置信区间(CI)。使用 STATA 软件(Stata 14,Stata 公司,德克萨斯州)和 Review Manager 5.4 进行荟萃分析。
共纳入来自 16 项研究的 4500 名患者。与 CDG 组相比,PPG 组的淋巴结清扫数目较少(WMD=-3.09;95%CI-4.75 至-1.43;P<0.001)。在第 5、6、9 和 11p 站观察到淋巴结清扫数量的差异。各站淋巴结转移无差异。PPG 组近端切除边缘较短(WMD=-0.554;95%CI-0.999 至-0.108;P=0.015)和远端切除边缘较短(WMD=-1.569;95%CI-3.132 至-0.007;P=0.049)。PPG 组的病理 T1a 期(OR=0.99;95%CI 0.80 至 1.23;P=0.88)、T1b 期(OR=1.01;95%CI 0.81 至 1.26;P=0.88)、N0 期(OR=0.97;95%CI 0.63 至 1.48;P=0.88)、肿瘤大小(WMD=-0.10;95%CI-0.25 至 0.05;P=0.187)、分化型癌(OR=1.04;95%CI 0.74 至 1.47;P=0.812)或印戒细胞癌(OR=1.22;95%CI 0.90 至 1.64;P=0.198)无显著差异。两组之间的总生存(HR=0.63;95%CI 0.24 至 1.67;P=0.852)或无复发生存(HR=0.29;95%CI 0.03 至 2.67;P=0.900)无显著差异。
对现有证据的荟萃分析表明,PPG 的生存结果可能与 CDG 相当。然而,PPG 时第 5、6、9 和 11p 站的淋巴结清扫数目较少。我们还发现 PPG 的近端切除边缘和远端切除边缘较短,这意味着 PPG 会保留更多的残胃。